...Okay. Welcome, everyone. We'll continue with the next session. My name is Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome the management team from PTC. To my immediate right, we have Dr. Matt Klein. And at the far end there, we have Kylie O'Keefe. What we'll do is the usual format. Maybe I'll let Matt kick it off with a couple of high-level comments, and then we'll go into Q&A. If anybody in the audience has questions along the way, please feel free to raise your hand, and we'll get a mic to you. Also, for those who are listening on the webcast, if you have any questions, please e-mail them to us, and we'll read them anonymously if time allows. But otherwise, with that, I'll let Matt kick it off here. Matthew B. Klein ...
